ImmunoGen files NHL drug IND with FDA
Developed by ImmunoGen, IMGN529 is indicated as a treatment for B-cell malignancies including non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). ImmunoGen president and CEO Daniel Junius said
The Liverpool School of Tropical Medicine (LSTM) in the UK has opened a £20m ($23.2m) robotic AI laboratory to test drugs and vaccines against infections and diseases.